drugset / Trial / NCT06153173
Mirdametinib in Histiocytic Disorders
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Timeline
- Start
- 2024-02-05
- Primary completion
- 2030-03
- Completion
- 2031-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | 2 mg/m2 | Oral |